[Expression of six gene proteins in laryngeal carcinomas and their significance].
OBJECTIVE
To investigate the expression of p15, p16, Rb, p27,p53 and PCNA gene proteins in different clinical stage, different position and different histological types of laryngeal carcinomas and their significance.


METHODS
p15, p16, Rb, p27, p53 and PCNA gene proteins were examined with immunohistochemical SP method in the paraffin-embedded specimens of 65 cases with LSCC and 30 cases of normal or proliferative mucosas of larynx as a contrast. The result was analyzed by chi-square test.


RESULTS
The expression of the six gene proteins in LSCC and in laryngeal with normal or proliferative mucosas was different, the difference was significant (P < 0.01); the expression of p15 and p27 was significantly related with the position/clinical stage/histological types of LSCC (P < 0.01); the expression of p16 was significantly negative but the PCNA was positive correlated with th histological types of LSCC (P < 0.01). Two of them did not correlate with the position or clinical stage of LSCC (P > 0.05). There was trend of the decreasing Rb expression or increasing p53 expression with increasing clinical stages of LSCC, and the expression of p53 was also positive correlated with the histological types of LSCC.


CONCLUSIONS
p15 and p27 play an important role in the development and progression of LSCC, and can be used as markers for assessment the treatment and prognosis of LSCC. The expression of p16 and PCNA can reflect the proliferation activity in the tumor cells, and is correlated with the development of tumor, but it does not correlate with the progression of tumor. The expression of Rb and p53 were more correlated with the progression of tumor.
Wu
Xianguang
X
Department of Otolaryngology-Head and Neck Surgery, Second Affiliated Hospital of Shantou University Medical College, Shantou 515042, China.
He
Shuhua
S
Wu
Mingyao
M
Zhou
Liang
L
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D016022:Case-Control Studies; D050762:Cyclin-Dependent Kinase Inhibitor p15 / Q000378:metabolism; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000378:metabolism; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D009367:Neoplasm Staging; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D050762:Cyclin-Dependent Kinase Inhibitor p15; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; D018809:Proliferating Cell Nuclear Antigen; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53; D050760:Cyclin-Dependent Kinase Inhibitor p27